359 related articles for article (PubMed ID: 26657115)
1. IL-27 induces the expression of IDO and PD-L1 in human cancer cells.
Carbotti G; Barisione G; Airoldi I; Mezzanzanica D; Bagnoli M; Ferrero S; Petretto A; Fabbi M; Ferrini S
Oncotarget; 2015 Dec; 6(41):43267-80. PubMed ID: 26657115
[TBL] [Abstract][Full Text] [Related]
2. Targetable Immune Regulatory Molecule Expression in High-Grade Serous Ovarian Carcinomas in African American Women: A Study of PD-L1 and IDO in 112 Cases From the African American Cancer Epidemiology Study (AACES).
Mills AM; Peres LC; Meiss A; Ring KL; Modesitt SC; Abbott SE; Alberg AJ; Bandera EV; Barnholtz-Sloan J; Bondy ML; Cote ML; Funkhouser E; Moorman PG; Peters ES; Schwartz AG; Terry PD; Wallace K; Schildkraut JM
Int J Gynecol Pathol; 2019 Mar; 38(2):157-170. PubMed ID: 29485423
[TBL] [Abstract][Full Text] [Related]
3. Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC.
Della Corte CM; Ciaramella V; Ramkumar K; Vicidomini G; Fiorelli A; Nardone V; Cappabianca S; Cozzolino I; Zito Marino F; Di Guida G; Wang Q; Cardnell R; Gay CM; Ciardiello D; Martinelli E; Troiani T; Martini G; Napolitano S; Wang J; Byers LA; Ciardiello F; Morgillo F
J Transl Med; 2022 Nov; 20(1):541. PubMed ID: 36419183
[TBL] [Abstract][Full Text] [Related]
4. Clinical Significance of Program Death Ligand-1 and Indoleamine-2,3-Dioxygenase Expression in Colorectal Carcinoma.
Hacking S; Vitkovski T; Jain S; Jin C; Chavarria H; Wu D; Nasim M
Appl Immunohistochem Mol Morphol; 2021 Mar; 29(3):201-208. PubMed ID: 32842025
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer.
Webb JR; Milne K; Kroeger DR; Nelson BH
Gynecol Oncol; 2016 May; 141(2):293-302. PubMed ID: 26972336
[TBL] [Abstract][Full Text] [Related]
6. [Expression and significance of PD-1 and PD-L1 in the specimens of epithelial ovarian cancer].
Ju C; Gao JC; Zhang PX; Zhang KN; Yang S; Kang TJ; Zhao HZ; Qi WJ; Zhang QP; Kong FD; Guan HW; Shi H
Zhonghua Fu Chan Ke Za Zhi; 2020 Aug; 55(8):529-534. PubMed ID: 32854477
[No Abstract] [Full Text] [Related]
7. Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer.
Schalper KA; Carvajal-Hausdorf D; McLaughlin J; Altan M; Velcheti V; Gaule P; Sanmamed MF; Chen L; Herbst RS; Rimm DL
Clin Cancer Res; 2017 Jan; 23(2):370-378. PubMed ID: 27440266
[TBL] [Abstract][Full Text] [Related]
8. Ovarian cancer immunotherapy using PD-L1 siRNA targeted delivery from folic acid-functionalized polyethylenimine: strategies to enhance T cell killing.
Teo PY; Yang C; Whilding LM; Parente-Pereira AC; Maher J; George AJ; Hedrick JL; Yang YY; Ghaem-Maghami S
Adv Healthc Mater; 2015 Jun; 4(8):1180-9. PubMed ID: 25866054
[TBL] [Abstract][Full Text] [Related]
9. Indoleamine-2,3-Dioxygenase in Non-Small Cell Lung Cancer: A Targetable Mechanism of Immune Resistance Frequently Coexpressed With PD-L1.
Volaric A; Gentzler R; Hall R; Mehaffey JH; Stelow EB; Bullock TN; Martin LW; Mills AM
Am J Surg Pathol; 2018 Sep; 42(9):1216-1223. PubMed ID: 29901571
[TBL] [Abstract][Full Text] [Related]
10. Landscape of Immune Checkpoint Inhibition in Carcinosarcoma (MMMT): Analysis of IDO-1, PD-L1 and PD-1.
Hacking S; Chavarria H; Jin C; Perry A; Nasim M
Pathol Res Pract; 2020 Apr; 216(4):152847. PubMed ID: 32085927
[TBL] [Abstract][Full Text] [Related]
11. The IL-18 antagonist IL-18-binding protein is produced in the human ovarian cancer microenvironment.
Carbotti G; Barisione G; Orengo AM; Brizzolara A; Airoldi I; Bagnoli M; Pinciroli P; Mezzanzanica D; Centurioni MG; Fabbi M; Ferrini S
Clin Cancer Res; 2013 Sep; 19(17):4611-20. PubMed ID: 23873689
[TBL] [Abstract][Full Text] [Related]
12. An IL-27/Stat3 axis induces expression of programmed cell death 1 ligands (PD-L1/2) on infiltrating macrophages in lymphoma.
Horlad H; Ma C; Yano H; Pan C; Ohnishi K; Fujiwara Y; Endo S; Kikukawa Y; Okuno Y; Matsuoka M; Takeya M; Komohara Y
Cancer Sci; 2016 Nov; 107(11):1696-1704. PubMed ID: 27564404
[TBL] [Abstract][Full Text] [Related]
13. Expression of STAT1 is positively correlated with PD-L1 in human ovarian cancer.
Liu F; Liu J; Zhang J; Shi J; Gui L; Xu G
Cancer Biol Ther; 2020 Oct; 21(10):963-971. PubMed ID: 33043814
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-22 attenuates double-stranded RNA-induced upregulation of PD-L1 in airway epithelial cells via a STAT3-dependent mechanism.
Seki N; Kan-O K; Matsumoto K; Fukuyama S; Hamano S; Tonai K; Ota K; Inoue H; Nakanishi Y
Biochem Biophys Res Commun; 2017 Dec; 494(1-2):242-248. PubMed ID: 29032197
[TBL] [Abstract][Full Text] [Related]
15. [Expression and prognostic values of PD-1, PD-L1 and IDO-1 in sinonasal malignant mucosal melanoma].
Liu HQ; Zou BQ; Wang SY
Zhonghua Bing Li Xue Za Zhi; 2017 Nov; 46(11):782-788. PubMed ID: 29136692
[No Abstract] [Full Text] [Related]
16. Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR.
Litzenburger UM; Opitz CA; Sahm F; Rauschenbach KJ; Trump S; Winter M; Ott M; Ochs K; Lutz C; Liu X; Anastasov N; Lehmann I; Höfer T; von Deimling A; Wick W; Platten M
Oncotarget; 2014 Feb; 5(4):1038-51. PubMed ID: 24657910
[TBL] [Abstract][Full Text] [Related]
17. Impact of sidedness of colorectal cancer on tumor immunity.
Takasu C; Nishi M; Yoshikawa K; Tokunaga T; Kashihara H; Yoshimoto T; Shimada M
PLoS One; 2020; 15(10):e0240408. PubMed ID: 33045001
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms regulating PD-L1 expression on tumor and immune cells.
Chen S; Crabill GA; Pritchard TS; McMiller TL; Wei P; Pardoll DM; Pan F; Topalian SL
J Immunother Cancer; 2019 Nov; 7(1):305. PubMed ID: 31730010
[TBL] [Abstract][Full Text] [Related]
19. Indoleamine 2,3-dioxygenase regulates T cell activity through Vav1/Rac pathway.
Li R; Li H; Sun Q; Liu L; Zhang C; Ren X
Mol Immunol; 2017 Jan; 81():102-107. PubMed ID: 27930920
[TBL] [Abstract][Full Text] [Related]
20. The role of the immunoescape in colorectal cancer liver metastasis.
Takasu C; Yamashita S; Morine Y; Yoshikawa K; Tokunaga T; Nishi M; Kashihara H; Yoshimoto T; Shimada M
PLoS One; 2021; 16(11):e0259940. PubMed ID: 34797860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
